title: Adhesion of endothelial cells to NOV is mediated by the integrins alphavbeta3 and alpha5beta1.
abstract: NOV is a member of the CCN family of matricellular proteins. We have shown previously that NOV is strongly expressed by vascular smooth muscle cells (VSMCs) of the rat carotid artery. However, 7 days after injury, NOV expression is down-regulated, except near the luminal surface of the developing intima, where it is strongly expressed. These data suggested that NOV might be involved in the regulation of endothelial cell adhesion. NOV promoted the adhesion of human umbilical vein endothelial cells (HUVECs), which was abolished by anti-NOV antibody. HUVEC adhesion to NOV required divalent cations and was inhibited by GRGDS peptide, implicating integrins in the adhesion mechanism. Monoclonal antibodies (mAbs) against alphavbeta3 inhibited adhesion of HUVECs to NOV, and NOV was shown to bind to alphavbeta3. Anti-alpha5beta1 mAbs also inhibited HUVEC adhesion to NOV, but adhesion via alpha5beta1 was mediated by fibronectin. HUVEC adhesion to NOV caused intracellular signalling, as evidenced by increased phosphotyrosine content of focal adhesion kinase. Together with evidence that NOV expression in a variety of tissues is restricted to blood vessels containing VSMCs, these data are consistent with a role for NOV in endothelial cell adhesion in vascular homeostasis and in the response to injury.
authors.affiliation: Section of Cardiovascular Biology, University of Cambridge, Cambridge, UK. pde1001@mole.bio.cam.ac.uk
authors.forename: Peter D
authors.initials: PD
authors.lastname: Ellis
authors.forename: James C
authors.initials: JC
authors.lastname: Metcalfe
authors.forename: Marko
authors.initials: M
authors.lastname: Hyvönen
authors.forename: Paul R
authors.initials: PR
authors.lastname: Kemp
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002448:Cell Adhesion / Q000502:physiology; D002478:Cells, Cultured; D055513:Connective Tissue Growth Factor; D004730:Endothelium, Vascular / Q000166:cytology / Q000502:physiology*; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; D006801:Humans; D017874:Immediate-Early Proteins / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D039081:Integrin alpha5beta1 / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D039302:Integrin alphaVbeta3 / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D055514:Nephroblastoma Overexpressed Protein; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D051381:Rats; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; C526317:CCN2 protein, human; C526316:CCN2 protein, rat; C526319:CCN3 protein, human; D017874:Immediate-Early Proteins; D039081:Integrin alpha5beta1; D039302:Integrin alphaVbeta3; D036341:Intercellular Signaling Peptides and Proteins; D055514:Nephroblastoma Overexpressed Protein; D055513:Connective Tissue Growth Factor; D011505:Protein-Tyrosine Kinases; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; C496050:PTK2 protein, human; C496052:Ptk2 protein, rat